ArticleAngewandte Chemie (International ed. in English)2013
Chelator-free synthesis of a dual-modality PET/MRI agent.
Article in Angewandte Chemie (International ed. in English), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Targeting osteopontin with gold nanoparticles for enhanced molecular imaging in Kawasaki disease: in-depth mechanistic study of STAT3 signaling in Col1 regulation.Journal of translational medicine · 2026Article
- Radiolabeled Iron-Based Nanomaterials for Cancer Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- Multimodal imaging in cancer detection: the role of SPIONs and USPIONs as contrast agents for MRI, SPECT, and PET.Future oncology (London, England) · 2025Review
- Nanomaterial-Based Molecular Imaging in Cancer: Advances in Simulation and AI Integration.Biomolecules · 2025Review
- Cancer Brachytherapy at the Nanoscale: An Emerging Paradigm.Chemical & biomedical imaging · 2024Review
- Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts.Cancer nanotechnology · 2023Review
- Chelator-Free Copper-64-Incorporated Iron Oxide Nanoparticles for PET/MR Imaging: Improved Radiocopper Stability and Cell Viability.Nanomaterials (Basel, Switzerland) · 2022Article
- Preliminary Evaluation of Iron Oxide Nanoparticles Radiolabeled withNanomaterials (Basel, Switzerland) · 2022Article
- Recent advances in engineering iron oxide nanoparticles for effective magnetic resonance imaging.Bioactive materials · 2022Review
- Imaging Constructs: The Rise of Iron Oxide Nanoparticles.Molecules (Basel, Switzerland) · 2021Review
- Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges.International journal of nanomedicine · 2021Review
- Magnetic Nanoparticles in Cancer Therapy and Diagnosis.Advanced healthcare materials · 2020Review
- Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma.ACS nano · 2020Article
- Gold-based Inorganic Nanohybrids for Nanomedicine Applications.Theranostics · 2020Review
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Therapeutic Isotopes.International journal of nanomedicine · 2020Article
- Bovine serum albumin-templated nanoplatform for magnetic resonance imaging-guided chemodynamic therapy.Journal of nanobiotechnology · 2019Article
- Surface radio-mineralisation mediates chelate-free radiolabelling of iron oxide nanoparticles.Chemical science · 2019Article
- Multimodality Imaging Agents with PET as the Fundamental Pillar.Angewandte Chemie (International ed. in English) · 2019Review
- Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities.Biomaterials · 2018Article
- General synthesis of silica-based yolk/shell hybrid nanomaterials andNano research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.